Netrine 4 mutee, ses fragments et leur utilisation comme medicaments

Mutated netrin-4, fragments thereof and their use as medicines

Abstract

The invention concerns the use of a netrin selected among netrin-4, mutated netrin-4, netrin-1, netrin Gl or netrin-3, or one of their fragments or a nucleotide sequence encoding one of said netrins or one of said fragments, or an anti-idiotypic antibody of one of said netrins or of one of said fragments, or of a Fab fragment of said anti-idiotypic antibodies, for preparing a medicine for preventing or treating tumoral or non-tumoral pathologies.
La présente invention concerne l'utilisation d'une nétrine choisie parmi la nétrine 4, la nétrine 4 mutée, la nétrine 1, la nétrine Gl ou la nétrine 3, ou l'un de leurs fragments, ou d'une séquence nucléotidique codant pour l'une de ces nétrines ou l'un de ces fragments, ou d'un anticorps anti-idiotypique de l'une de ces nétrines ou de l'un de ces fragments, ou d'un fragment Fab desdits anticorps anti-idiotypiques, pour la préparation d'un médicament destiné à la prévention ou au traitement des pathologies tumorales ou non tumorales.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (3)

    Publication numberPublication dateAssigneeTitle
    US-6218526-B1April 17, 2001The Regents Of The University Of California, Exelixis Pharmaceuticals, Inc.Polynucleotide encoding human netrin-1
    WO-0154723-A1August 02, 2001Sunnybrook Health Science Center, Imclone Systems IncorporatedTherapeutic method for reducing angiogenesis
    WO-0164837-A2September 07, 2001The General Hospital CorporationNETRINE β ET SES UTILISATIONS

NO-Patent Citations (2)

    Title
    KOCH M ET AL: "A NOVEL MEMBER OF THE NETRIN FAMILY, BETA-NETRIN, SHARES HOMOLOGY WITH THE BETA CHAIN OF LAMININ: IDENTIFICATION, EXPRESSION, AND FUNCTIONAL CHARACTERIZATION" THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 151, no. 2, 16 octobre 2000 (2000-10-16), pages 221-234, XP002944911 ISSN: 0021-9525
    See also references of EP 1814579A2

Cited By (21)

    Publication numberPublication dateAssigneeTitle
    EP-1947114-A1July 23, 2008INSERM (Institut National de la Santé et de la Recherche Médicale), The Centre National de la Recherche Scientifique, I.V.S. Institut Des Vaisseaux Et Du SangMutated netrin 4, fragments thereof and uses thereof as drugs
    EP-2708231-A1March 19, 2014Netris PharmaCombined treatment with netrin-1 interfering drug and chemotherapeutic drug
    EP-3037817-A1June 29, 2016Osaka UniversityMethod for screening pain inhibitor and medicinal composition for preventing or treating pain
    EP-3037817-A4April 05, 2017Univ OsakaMethod for screening pain inhibitor and medicinal composition for preventing or treating pain
    JP-2010516237-AMay 20, 2010アイヴィーエス アンスティテュ デ ベソー エ ドュ サンIvs Institut Des Vaisseaux Et Du Sang, アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル(アンセルム)Institut National De La Sante Et De La Recherche Medicale(Inserm), サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク変異ネトリン4、そのフラグメント及び薬剤としてのその使用
    US-7981420-B2July 19, 2011Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V.Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)
    US-8906864-B2December 09, 2014AbbVie Deutschland GmbH & Co. KGBinding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
    US-9050298-B2June 09, 2015The Regents Of The University Of CaliforniaMethod of treating ischemia/reperfusion injuries to a heart with netrin-1
    US-9102722-B2August 11, 2015AbbVie Deutschland GmbH & Co. KG, Abbvie Inc.Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
    US-9175075-B2November 03, 2015AbbVie Deutschland GmbH & Co. KGMethods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
    US-9365643-B2June 14, 2016AbbVie Deutschland GmbH & Co. KG, Abbvie Inc.Antibodies that bind to repulsive guidance molecule A (RGMA)
    US-9605069-B2March 28, 2017AbbVie Deutschland GmbH & Co. KG, Abbvie Inc.Antibodies against the RGM a protein and uses thereof
    WO-2008087224-A2July 24, 2008Inserm (Institut National De La Sante Et De La Recherche Medicale), Centre National De La Recherche Scientifique, Ivs Institut Des Vaisseaux Et Du Sang, PLOUËT, Isabelle, Clarisse, Solange, PLOUËT, Claire, Charlotte, PLOUËT, Anne, FlorenceMutated netrin 4, fragments thereof and uses thereof as drugs
    WO-2008087224-A3September 25, 2008Inst Nat Sante Rech Med, Centre Nat Rech Scient, Ivs Inst Des Vaisseaux Et Du S, Jean Plouet, Laurence Leconte, Esma LejmiNetrine 4 mutée, fragments de cette dernière et utilisations comme médicament
    WO-2010007144-A2January 21, 2010Centre National De La Recherche Scientifique, PLOUËT, Isabelle, Clarisse, Solange, PLOUËT, Claire, Charlotte, PLOUËT, Anne, FlorenceNew mutated netrin 4 proteins, fragments thereof and their uses as drugs
    WO-2010007144-A3March 11, 2010Centre National De La Recherche Scientifique, PLOUËT, Isabelle, Clarisse, Solange, PLOUËT, Claire, Charlotte, PLOUËT, Anne, FlorenceNouvelles protéines de nétrine 4 mutées, fragments de celles-ci et leurs utilisations en tant que médicaments
    WO-2011150299-A2December 01, 2011The Regents Of The University Of CaliforniaTreatment of myocardial infarction and vascular injury with netrin-1
    WO-2011150299-A3April 05, 2012The Regents Of The University Of CaliforniaTraitement d'infarctus du myocarde et de lésion vasculaire par nétrine-1
    WO-2014041088-A2March 20, 2014Netris PharmaPolythérapie comprenant un médicament interférant avec la nétrine-1 et un médicament chimiothérapeutique
    WO-2014041088-A3July 03, 2014Netris PharmaPolythérapie comprenant un médicament interférant avec la nétrine-1 et un médicament chimiothérapeutique